EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment

Yuze Zhao, Yuguang Song, Weiping Li, Jiangping Wu, Zhengbao Zhao, Tingli Qu, Hong Xiao, Manyuan Wang, Min Zhu, Peiming Zheng, Huili Wan, Qingkun Song und 2 weitere

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-03994-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yuze Zhao und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, Chi…. Hauptthemen laut MEDLINE: Glioblastoma, Clofazimine, Tumor Microenvironment, Programmed Cell Death 1 Receptor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Shijitan Hospital Youth Found, Beijing research center for respiratory infectious diseases project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme (GBM) is an aggressive and lethal primary brain tumor with limitedtreatment options due to its resistance to conventional therapies and an immunosuppressive tumor microenvironment. In this study, we investigated whether clofazimine, an inhibitor of the Wnt/β-catenin signaling pathway, could enhance the efficacy of anti-PD-1 immunotherapy in GBM. Our in vitro and in vivo experiments demonstrated that clofazimine suppressed GBM cell proliferation, induced apoptosis, and inhibited invasion by downregulating Wnt6-mediated activation of the Wnt/β-catenin pathway and the downstream MEK/ERK signaling cascade, leading to decreased PD-L1 expression. Notably, the combination of clofazimine and anti-PD-1 therapy significantly reduced tumor growth and intracranial invasion in orthotopic GBM mouse models, resulting in extended survival. This combination therapy also reshaped the tumor immune microenvironment by increasing cytotoxic CD8+ T cell infiltration, reducing regulatory T cells, and promoting T cell receptor clonality and diversity, indicative of a robust anti-tumor immune response. Our findings suggest that clofazimine enhances the therapeutic effects of anti-PD-1 immunotherapy in GBM through modulation of the Wnt6/β-catenin/PD-L1 axis and reshaping the immune microenvironment. While these results are promising, further clinical studies are needed to evaluate the efficacy and safety of this combinatory approach in GBM patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaClofazimineTumor MicroenvironmentProgrammed Cell Death 1 ReceptorBrain NeoplasmsImmunotherapyImmune Checkpoint InhibitorsWnt ProteinsAnimalsHumansMiceWnt Signaling PathwayCell Line, TumorXenograft Model Antitumor AssaysCell Proliferation

Stichwörter der Autor:innen

Anti-PD-1 immunotherapyClofazimineGlioblastomaTumor immune microenvironmentWnt6 signaling pathway

Substanzen

ClofazimineProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsWnt ProteinsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
  • Department of Radiotherapy, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, 100038, China.
  • Department of Pharmacology, Shanxi Medical University Fenyang College, Fenyang, 032200, China.
  • Department of Center of Biobank, Beijing Youan Hospital, Capital Medical University, Beijing, 100069, China.
  • Department of Pharmacy, Shanxi Medical University, Taiyuan, 030001, China.
  • Department of Pathology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China.

Förderung

  • Beijing Shijitan Hospital Youth Found
  • Beijing research center for respiratory infectious diseases project

Zitieren

APA

Zhao, Y., Song, Y., Li, W., Wu, J., Zhao, Z., Qu, T., Xiao, H., Wang, M., Zhu, M., Zheng, P., Wan, H., Song, Q., Zheng, H., & Wang, S. (2025). Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-03994-5

Vancouver

Zhao Y, Song Y, Li W, Wu J, Zhao Z, Qu T, et al. Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-03994-5

BibTeX
@article{Zhao2025,
  author = {Zhao, Yuze and Song, Yuguang and Li, Weiping and Wu, Jiangping and Zhao, Zhengbao and Qu, Tingli and Xiao, Hong and Wang, Manyuan and Zhu, Min and Zheng, Peiming and Wan, Huili and Song, Qingkun and Zheng, Huixia and Wang, Shuo},
  title = {Clofazimine enhances anti-PD-1 immunotherapy in glioblastoma by inhibiting Wnt6 signaling and modulating the tumor immune microenvironment},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-03994-5}
}
Kostenlos starten →